Targeted radiation for advanced digestive cancers
Part of Cancer clinical trials.
This trial tests a special radioactive medicine (177Lu-CTR-FAPI) for people with advanced digestive cancers that have high FAP expression. The medicine targets a protein on cancer cells to deliver radiation directly to tumors, potentially slowing their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced digestive system cancer that has spread and cannot be removed by surgery.
- Your tumor shows high FAP expression on a PET scan (a special imaging test).
- You are in good physical condition (able to carry on daily activities).
- Your kidney, liver, and blood counts are within acceptable levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests two radioactive medicines that first help doctors see tumors and, in some parts of the study, treat them. It may help people with advanced, hard-to-remove cancers that have a specific tumor marker (CA IX).
This study tests a new type of PET scan that uses a radioactive tracer called FAPI-74 to find cancer spread in people with pancreatic cancer. The goal is to see if this scan can help doctors better plan treatment.
This trial tests a radioactive drug called 177Lu-CTR-FAPI for people with advanced solid tumors that have not responded to standard treatments. It targets tumors that show a specific protein (FAP) on PET scans. The study focuses on certain cancers like pancreatic, breast, and soft tissue sarcoma.
This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.
This trial tests a new radioactive drug (177Lu-FAP-2286) for advanced bladder cancer that has stopped responding to standard treatments. The drug targets a protein on the cancer cells to deliver radiation directly to them, with the goal of shrinking tumors and controlling the disease.
This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.
Hear when a new Pancreatic Ductal Adenocarcinoma (PDAC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.